Soleno Therapeutics (NASDAQ:SLNO) has been assigned a $4.00 price objective by investment analysts at Maxim Group in a research report issued on Monday. The firm currently has a “buy” rating on the stock. Maxim Group’s price objective points to a potential upside of 47.06% from the stock’s current price.
SLNO has been the topic of a number of other research reports. Roth Capital started coverage on shares of Soleno Therapeutics in a report on Friday, June 22nd. They set a “buy” rating and a $14.00 price objective on the stock. ValuEngine raised shares of Soleno Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Finally, Noble Financial set a $4.00 price objective on shares of Soleno Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 16th. Five equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $7.50.
SLNO stock traded up $0.18 during trading on Monday, reaching $2.72. 1,500 shares of the company were exchanged, compared to its average volume of 46,976. The company has a market cap of $50.21 million, a P/E ratio of -2.01 and a beta of 5.10. Soleno Therapeutics has a 52-week low of $1.32 and a 52-week high of $3.70.
Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, May 16th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.08). analysts predict that Soleno Therapeutics will post -1.37 earnings per share for the current year.
In other Soleno Therapeutics news, major shareholder Larry N. Feinberg purchased 50,000 shares of Soleno Therapeutics stock in a transaction on Tuesday, May 15th. The shares were bought at an average price of $1.80 per share, with a total value of $90,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 43.27% of the stock is currently owned by insiders.
A hedge fund recently bought a new stake in Soleno Therapeutics stock. Trellus Management Company LLC purchased a new stake in Soleno Therapeutics Inc (NASDAQ:SLNO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 129,243 shares of the company’s stock, valued at approximately $302,000. Trellus Management Company LLC owned approximately 0.65% of Soleno Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 45.79% of the company’s stock.
About Soleno Therapeutics
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development.
Further Reading: Average Daily Trade Volume – What It Means In Stock Trading
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.